HER2/neu amplification/overexpression is the only somatic mutation widely considered to be a marker ofdisease outcome and response to treatment in breast cancer. Pathologists have made large efforts to achieveaccuracy in characterizing HER2/neu status. The introduction of transtuzumab contributed to development ofadditional measures to identify sensitive and resistant subclasses of HER2/neu-positive tumors. In this article,we describe the latest advances in HER2/neu status diagnostic assessment and the most relevant researchemerging from ‘‘Omics’’ (genomics, epigenetics, transcriptomics, and proteomics) studies on HER2/neu-positivebreast cancer. A large quantity of biomarkers from different studies highlighted HER2/neu-positive specificproliferation, cell cycle arrest, and apoptosis mechanisms, as well as immunological and metabolic behavior.Major driver genes of tumor progression have had a candidate status (GRB7, MYC, CCND1, EGFR, etc.), eventhough the main role for HER2/neu is largely recognized. Nonetheless, existing omics data and HER2/neupositivemolecular profiles seem to suggest that few proteogenomic alterations in HER2, EGFR, and PI3Knetworks could significantly affect the effectiveness of transtuzumab. The systematic search of molecular alterationsin and across these pathways can help to select the most appropriate drug for a given patient based onin-depth understanding of complexity in tumor biology.
|Number of pages||11|
|Publication status||Published - 2013|
All Science Journal Classification (ASJC) codes
- Molecular Medicine
- Molecular Biology